People | February 17, 2026
Roche appoints Mark Dawson as new Head of Pharma Research and Early Development
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Subscribe To Our Newsletter & Stay Updated
